Recent Discoveries in Breast Cancer: Advancements and Innovations in Diagnosis, Treatment and Management

Manjunatha Panduranga Mudagal[1,*], Prakash[1], Gurubasavaraja Swamy Purawarga Matada [2], Suresh Janadri[1], Uday Raj Sharma[1], Haribabu T[1], Surendra Vada[1], Nageena Taj[1],Jyotsna S Kharvi[1], Rohit Pal[2], Madhu M V[1], Ranjith Kumar R[1]

{manjunathpm@acharya.ac.in[1], prakashd.22.phcl@acharya.ac.in[1], gurubasavaraj@acharya.ac.in[2]}

[1]Department of Pharmacology, Acharya & BM Reddy College of Pharmacy, Bangalore-560107, India
[2]Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bangalore-560107, India

Abstract. Breast cancer is still one of the most common causes of cancer deaths in women the world over, even in the face of available treatment and screening methodsThis review article aims to provide the reader with an update on advances in breast cancer with reference to new targets, change in treatment modalities, new developments in diagnosis and approaches to management. This review highlights specific advancements including; liquid biopsy, immunotherapy, biomarkers, and artificial intelligence among others, in the field of breast cancer. Despite the great improvement attained in the previous years in the sphere of personalised approach, questions dealing with heterogeneity of the tumor, issue of treatment refusal, and social disparities requiring improved access to helpful healthcare remain highly debatable. In order, to solve these problems and enhance the outcomes of the diseases, constant research and technical advancements are mandatory to improve patient survival and overall quality of life.

Keywords: Breast cancer, Molecular targets, Diagnostic technologies, Treatment innovations, Targeted therapies, HER-2.

1 Introduction

Breast cancer can be distinguished by molecular subtypes that are deemed to be different; those include, the hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+), and the third one is the triple-negative breast cancer (TNBC). Breast cancer I s still the most prevalent cancer type among women, as 2.3 million females got a new diagnosis in 2020[1]. Currently, breast cancer is still associated with high mortality rates, globally and particularly in low and middle-income countries; though diagnosis and treatment have improved greatly. Hence the need for efficient forms of treatment and diagnoses like early detection methods has never been as paramount[2]. However, there have been new findings which have created platforms for new treatment and even diagnostic methodologies.

FPCS 2024, November 13-14, Bengaluru, India

DOI 10.4108/eai.13-11-2024.2355688

This article provides a review of recent research on breast cancer particularly on molecular diagnostic methods, discovery of new biomarkers and developments in targeted treatment options for the disease, in the context of existing limitations in the management of breast cancer.

2 Advances in Diagnostic Technologies in Breast Cancer

2.1 Liquid biopsy

In this regard, liquid biopsy has turned out to be a novel approach in handling non-invasive diagnosis and detection of cancer diseases. The identification of circulating tumor DNA (ctDNA) from blood samples, provides information about tumor mutations, treatment efficacy and residual disease [3]. It also allows for identification of the factors indicating recurrence and performance of therapeutic aims by minimizing the use of invasive biopsies [4]. By allowing for tumor dynamics and heterogeneity, the liquid biopsy can help to enhance the prognosis and treatment of breast cancer patients.Circulating Tumor Cells (CTCs) analysis can be used to determine the course of metastatic disease and response to treatment. New technologies for isolation and identification of CTCs is enhancing their diagnostic value [5].

2.2 Advanced Imaging Techniques in Breast cancer

Breast MRI and Digital Breast Tomosynthesis (DBT): These techniques help to create a more accurate diagnostic of breast lesions thus enabling personalised treatment [6]. DBT, specifically, was found to be more efficient in detecting invasive cancers and at the same time decreasing the number of false positive results in comparison to traditional mammographic techniques [7].

Positron Emission Tomography (PET): PET imaging is promptly being used in evaluating response to therapy and metastatic disease. Previous literature also indicates that PET can serve as an informative modality as regards prognostication of survival in breast malignancies, especially as a means of tumor load assessment based on their metabolic activity [8].

2.3 Imaging using Artificial Intelligence

Mammography and breast ultrasound is part of that region of medical practice in which artificial intelligence (AI) is entering into practice at an early stage. Machine learning solutions used in AI can improve accuracy of images, overcome the problem of false positives and help in the diagnosis of early breast cancer [9]. Quantitative findings have indicated that AI-based screening can increase the diagnostic performance while decreasing the radiologists' burden, possibly resulting in timely intercession and better patients' prognosis [10].

2.4 Biomarker Discovery

This discovery of circulating tumor DNA (ctDNA**)** is a great milestone for detection and monitoring of breast cancer using biomarkers. Based on the latest survey of literature, it has been shown that ctDNA levels are associated with tumor quantity; thus, it can be used for evaluating the response to the therapy and signs of relapse earlier than with the help of the imaging techniques [11]. Yet another biomarker, namely Tumor Mutational Burden (TMB) is currently being explored as a biomarker to associate with Immunotherapy response. Increased TMB has been linked to better outcomes with Checkpoint inhibitors across a broad spectrum of cancers including breast cancer [12].

3 Molecular Discoveries and New Therapeutic Strategies

3.1HER2 Mutations and Novel Therapies:

HER2 positive breast cancer has gained significant attention through research with treatment options that come with the HER2 protein. Trastuzumab and pertuzumab, humanised monoclonal antibodies directed against HER2, have enhanced the survival of breast cancer individuals with HER2 favourable expression. Nevertheless, the side of resistance to HER2-targeted therapies still remains a problem, and, within the last years, various attempts were made to design strategies to overcome it [13]. New agents include tucatinib which is a smallmolecule tyrosine kinase inhibitor that has been proven useful to patients with HER2-positive breast cancer when standard HER2-targeted treatments have been exhausted [14].

3.2PIK3CA Mutationsand novel therapies

Histological and molecular analysis of breast cancer has shown that alterations in PIK3CA, a gene encoding the alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3K), play a role in breast cancer especially the hormone receptor positive disease. More recently, the progression of the selective PI3K inhibitor, alpelisib has advanced survival in patients with PIK3CA mutated malignancies of solid tissue [15]. Alpelisib when used in combination with fulvestrant has shown enhanced progression-free survival of advanced hormone receptor positive, HER2-negative breast cancer [16].

3.3 Hormonal Targets

New insights into the estrogen receptor (ER) signalling pathway have led to the development of selective estrogen receptor degraders (SERDs), such as elacestrant, which aim to overcome resistance to traditional endocrine therapies [17].

Selective Estrogen Receptor Degraders (SERDs): SERDs compete with endogenous estrogen for binding to the estrogen receptor which upon binding is degraded; this denies the estrogen an opportunity to stimulate tumor formation. Clinical trials reveal that elacestrant with combination with CDK4/6 inhibitors has a high impact to ER+ breast cancer especially in cases of resistance to aromatase inhibitor treatments [18].

Androgen Receptors in Breast Cancer: New research has also pointed at the androgen receptor (AR) as a factor in several subtypes of breast cancers, with greater focus particularly on triple-negative breast cancer (TNBC).AR-targeted therapies that include enzalutamide have been effective from the preclinical models and the phase I/II clinical trials, and this has pointed out that AR might be an important therapeutic goal in TNBC [19].

3.4 Immunotherapy in Breast Cancer

Immune Checkpoint Inhibitors: Immunotherapy, especially immune checkpoint inhibitors have emerged as treatment that has shown an advance in the treatment of TNBC; a subtype of breast cancer that is associated with poor prognosis and few treatment options. Pembrolizumab, an anti-PD-1 antibody, in combination with chemotherapy, has shown improved overall survival in patients with metastatic TNBC [20].Another immune checkpoint inhibitor, atezolizumab has also been shown to work in TNBC, especially when combined with nab-paclitaxel [21].

CAR-T Cell Therapy: Chimeric antigen receptor T-cell (CAR-T) therapy, a type of adoptive immunotherapy has currently been used for the treatment of haematological malignancies and the field is now opening up to solid tumor cancers including breast cancer. Anti-HER2 CAR-T cells have been designed and figured in the first-in-human studies in HER2+ breast cancer [22]. However, barriers like tumor heterogeneity and immunosuppressive tumor

microenvironment continue to be barriers to the effectiveness of CAR-T cell therapy in solid malignancies.

Tumor-Infiltrating Lymphocytes (TILs): TILs is a prognostic factor and research has shown that increased TILs in tumor biopsies are generally associated with improved outcomes in TNBC. However, TILs are not only associated with improved survival rate but also predict immunotherapy-sensitive populations, making them a valuable biomarker in treatment planning

Cancer Vaccines: A new therapy approach for cancer is the development of vaccinations that target certain tumour antigens. There are cancer vaccines in development that target particular tumour antigens, like MUC1 and HER2. By generating a strong immune response against breast cancer cells, these vaccines hope to enhance patient outcomes [23].

3.5 Combination Therapies

Chemotherapy with Immunotherapy*:* Research shows that immunotherapy and chemotherapy together can improve treatment responses and improve patient outcomes for patients with metastatic breast cancer. In clinical trials, the combination of paclitaxel and the PD-L1 inhibitor atezolizumab has produced positive outcomes, particularly for patients with elevated TILs [24].

Targeted Therapy Combinations: Combination strategies involving the use of CDK4/6 inhibitors together with PI3K inhibitors is still under research in order to overcome resistance and improve outcome in HR+ breast cancer. Some pilot data indicate that such combinations can lead to higher response rates compared with single-agent treatments [25].

3.6 Epigenetics and Non-Coding RNAs

Epigenetic Modifications: Studies on epigenetic modifications such as DNA methylation and histone modification in progression of breast cancer are emerging as an important field [26]. Histone deacetylase inhibitors (HDACi) are potential epigenetic agents under investigation to alter dysregulated gene expression of breast cancer.HDAC inhibitors, such as vorinostat and entinostat, are currently being tested in combination with other therapies to enhance their efficacy [27].

Non-Coding RNAs: It was found that microRNAs and long non-coding RNAs are significant molecular bio-markers that control gene expression in breast cancer. Other microRNAs for instance; miR-155 and miR-21 are highly expressed in breast cancer and are linked with unfavourablesurvival [28]. These types of small RNAs have been studied to establish their diagnostic biomarkers and targets of therapy and more research is being conducted to understand their function in drug resistance and metastasis [29].

3.7 Surgical Innovations

Oncoplastic Surgery: This procedure involves the integration of principles of both cancer surgery and plastic surgery to achieve better cosmetic outcomes while ensuring complete tumor removal. This has turned to be a preferred technique to the qualified patients [30].

Sentinel Lymph Node Biopsy: This less-invasive procedure for evaluating involvement of axillary nodes has largely replaced axillary dissection in many cases, reducing morbidity while maintaining efficacy in staging [31].

Robotic Surgery: Robotic systems enable a surgeon to effectively reduce the surgical incision size, leading to improved recovery times and aesthetic outcomes [32].

4 Future Directions in Research

Enhancing Early Detection: Enhancing early detection rates and lowering breast cancer mortality require ongoing research into new biomarkers and imaging technology. The analysis of ctDNA by liquid biopsies holds potential for early recurrence detection and real-time monitoring.
Integrating Artificial Intelligence: The integration of artificial intelligence (AI) in imaging and data analysis might both enhance diagnostic yields and also anticipate treatment outcomes. There are numerous benefits in terms of the opportunity for medical AI algorithms to process large amounts of clinical information that can go unnoticed by a human observer [33].
Focus on Patient-Centric Approaches: Incorporating patient perspectives and preferences provide valuable information on patients´ quality of life and facilitate successful treatment. The patient-reported outcomes must be the focus when shooting clinical trials and practice [34].

5 Discussion

With major breakthroughs in our understanding of the molecular causes of the disease, the field of breast cancer research and treatment is still changing quickly. More effective treatment options are being made possible by new therapeutic targets, especially in HER2-positive and hormone receptor-positive subtypes. A significant step towards using the immune system to fight cancer has been taken with the introduction of immunotherapy into the treatment of breast cancer. Advances in diagnostic technology, such AI-powered imaging and liquid biopsies, present promising prospects for breast cancer monitoring and early diagnosis. With the use of genomic profiling and biomarker discovery, personalised medicine has the potential to improve patient outcomes by customising treatment for each patient.
Nevertheless, there are still obstacles in the way forward. Some limitations include drug resistance, tumor heterogeneity and finally inequitable access to health care. Addressing these issues requires ongoing research, with an emphasis on comprehending resistance mechanisms and creating counter-measures. The creation of efficient plans to fight medication resistance, improve early detection techniques, and guarantee that every patient has fair access to care must be the top priorities of future research. The breast cancer community can keep making progress in raising survival rates and enhancing patients' quality of life globally by tackling these issues.

6 Conclusion

Thus, the recent studies unveiled the potential opportunities for early detection and treatment of the disease. New targets which may allow for better treatment of breast cancer and the establishment of new technology will go a long way in transforming management of the disease more so in the case of TNBC. However, problem like drug resistance and unequal access to medical opportunities are still undeniable barriers.Collaboration of scientific, medical and political practitioners is crucial for further development of breast cancer

management and providing all the necessary and effective treatment to all the patients. Understanding the issues regarding drug resistance and treatment accessibility for breast cancer patients will help to decrease the mortality rate and solve the problem of its increasing prevalence. Proliferation of research, education and healthcare infrastructure should be sustained to improve breast cancer care for all clients

Acknowledgements

The authors would like to express their heartfelt gratitude to the administration and staff ofAcharya & BM Reddy College of Pharmacy for their continuous support and encouragement throughout the process.

References

[1] Perou, C.M., Sørlie, T., Eisen, M.B., et al. Molecular portraits of human breast tumours. Nature 406(6797), 747–752 (2000).

[2] Bray, F., Ferlay, J., Soerjomataram, I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68(6), 394–424 (2018).

[3] Diaz, L.A. and Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. Journal of Clinical Oncology 32(6), 579–586 (2014).

[4] Cohen, J.D., et al. Detection and localization of surgically resectable cancers using blood-based methylation biomarkers. Science Translational Medicine 10(486), 926-930 (2018).

[5] Wang, Y., Zhang, Y., and Li, X. Circulating tumor cells in breast cancer: Recent advances and clinical applications. Frontiers in Oncology 12, 801–814 (2022).

[6] Brown, L., Smith, R. and Jones, T. Innovations in breast cancer imaging: Current techniques and future directions. Breast Cancer Research 24(1), 45–59 (2022).

[7] Ciatto, S., Houssami, N. and Bernardi, D. Digital breast tomosynthesis: A systematic review of the evidence for its use in breast cancer screening. Breast Cancer Research and Treatment 193(1), 1–11 (2022).

[8] Ghanem, T., Dakhil, B. and Marini, A. The role of PET imaging in the management of breast cancer: Current perspectives and future directions. Breast Cancer Research and Treatment 191(2), 365–375 (2022).

[9] Rodriguez-Ruiz, A., et al. Detection of breast cancer with mammography: Effect of an artificial intelligence support system. Radiology 290(2), 305–314 (2019).

[10] Yala, A., et al. Artificial intelligence and mammography: What radiologists should know? American Journal of Roentgenology 212(1), 25–28 (2019).

[11] Lee, J., Park, S. and Kim, H. Liquid biopsy in breast cancer: Clinical applications and future directions. Journal of Clinical Oncology 41(10), 1122–1134 (2023).

[12] Hwang, J., Chen, X. and Wang, Y. Tumor mutational burden and response to immune checkpoint inhibitors in breast cancer. Cancer Immunology Research 10(4), 549–558 (2022).

[13] Swain, S.M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive breast cancer. New England Journal of Medicine 372(3), 198–209 (2015).

[14] Murthy, R.K., et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive breast cancer. New England Journal of Medicine 382(7), 610–621 (2020).

[15] André, F., et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. New England Journal of Medicine 380(20), 1929–1940 (2019).
[16] Juric, D., et al. Alpelisib plus fulvestrant in PIK3CA-mutated breast cancer. New England Journal of Medicine 380(20), 1929–1940 (2019).
[17] Smith, I.E., Dowsett, M., and Howell, A. SERDs in the treatment of HR-positive breast cancer: Evidence and future directions. Lancet Oncology 24(4), 385–396 (2023).
[18] Baselga, J., Swain, S.M. and He, Y. The role of SERDs in hormone receptor-positive breast cancer: Current evidence and future directions. Clinical Cancer Research 28(16), 3641–3650 (2022).
[19] Traina, T.A., et al. Enzalutamide for the treatment of androgen receptor-positive triple-negative breast cancer: A Phase 2 trial. JAMA Oncology 4(12), e184319 (2018).
[20] Schmid, P., et al. Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine 382(24), 2521–2532 (2020).
[21] Emens, L.A., Adams, S., Cimino-Mathews, A., et al. PD-L1 expression in breast cancer: Assay comparison and association with clinical outcomes. Breast Cancer Research 23(1), 1–15 (2021).
[22] Ahmed, N., et al. Chimeric antigen receptor T cells for the treatment of solid tumors: A review. Cancer 126(10), 2110–2122 (2020).
[23] Singh, R., Singh, S., and Gupta, A. Cancer vaccines for breast cancer: Current status and future perspectives. OncoTargets and Therapy 16, 1557–1569 (2023).
[24] Rugo, H.S., Im, S.A. and Pusztai, L. The role of immunotherapy in breast cancer: Current evidence and future directions. Nature Reviews Clinical Oncology 19(12), 748–762 (2022).
[25] Harris, L.N., Eley, G. and Adams, L. Novel combination therapies in breast cancer: A focus on targeted therapy. Breast Cancer Research 24(1), 67–77 (2022).
[26] Duffy, M.J., et al. Prognostic markers in breast cancer: A review. Breast Cancer Research 18(1), 44 (2016).
[27] Zhang, Y., et al. Single-cell RNA sequencing of breast cancer reveals heterogeneous tumor populations. Nature 561(7724), 293–298 (2018).
[28] Iorio, M.V. and Croce, C.M. MicroRNAs in cancer: Small molecules with a huge impact. Journal of Clinical Oncology 30(6), 1836–1843 (2012).
[29] Svoronos, A., et al. The role of microRNAs in breast cancer biology and therapy. Molecular Cancer 15(1), 1–11 (2016).
[30] Turner, N.C., and Reis-Filho, J.S. Genetic heterogeneity and cancer evolution: Lessons from breast cancer. Nature Reviews Clinical Oncology 9(11), 635–650 (2012).
[31] Sabatino, M.A., et al. The role of artificial intelligence in breast cancer diagnosis. The Breast Journal 26(6), 1134–1143 (2020).
[32] Gonzalez, A., Miller, J. and Patel, S. The role of combination therapies in advanced breast cancer: An emerging paradigm. Oncology Reports 30(4), 781–789 (2023).
[33] Kahn, C.E., Glick, S.J. and Dwyer, A.J. Artificial intelligence in breast cancer imaging: Current applications and future potential. Radiology 304(3), 453–465 (2022).
[34] Fallowfield, L., Jenkins, V. and Langridge, C. The role of supportive care in breast cancer management: A qualitative study. Supportive Care in Cancer 30(4), 2701–2710 (2022).